Jaguar Gene Therapy LLC

Illinois

Classification

Private

About

About

Jaguar Gene Therapy LLC is a privately-held biotechnology company that specializes in the development and commercialization of innovative gene therapies to treat various genetic disorders. The company is committed to advancing the field of gene therapy by creating safe and effective treatments that target the root cause of genetic diseases. Jaguar Gene Therapy LLC uses cutting-edge technology to develop gene therapies that can cure or alleviate genetic disorders. The company's research focuses on identifying genetic targets that are responsible for disease and developing therapies that can correct or replace the faulty genes. The company's gene therapies are designed to provide long-term solutions to genetic disorders and have the potential to transform the lives of patients. Jaguar Gene Therapy LLC was founded in 2019. Jaguar Gene Therapy LLC headquarters are located in Lake Forest, Illinois.

Financials

Revenue & Profit

Revenue

Valuation

Valuation

Ratios

Revenue / EBITDA
$123 MM
Valuation / Revenue
$123 MM
Valuation / Employees
$123 MM
EBITDA / Revenue
$123 MM
1-Year CAGR (Revenue)
03
3-Year CAGR (Revenue)
11
1-Year CAGR (Employees)
19
3-Year CAGR (Employees)
96

People

Employee Figures

Employees

Key Executives

NameTitleSocialsEmailPhone
John DoeEmployee
--
Jane DoeEmployee
John DoeEmployee
John DoeEmployee

401K

Total Active Participants
1234
No. Participants with Account Balances
56789
Total Liabilities Start of Year
1234
Total Assets Start of Year
56789

Deals

M&A2024-03-15Completed

Seller

Founders Group

Investor Sponsors

NorthBridge PE

Deal Amount

$120M

Target Company Valuation

$1.20 MM

Techniques

Acquisition of Assets, Taken Private

Stake Tags

100%

Is PE deal

Yes

Is deal PE backed

Yes

Total Acquired

100%

Secondary Transaction2023-09-01Canceled

Target

BrightHealth Technologies

Seller

Early Investors Consortium

Investor Sponsors

--

Deal Amount

Undisclosed

Target Company Valuation

NaN

Techniques

Secondary Sale, Management Buy-out (MBO)

Stake Tags

Majority

Is PE deal

No

Is deal PE backed

Yes

Total Acquired

65%

Funding

Keywords

Keywords

Classified

Private